Literature DB >> 28059651

Automatic estimation of extent of resection and residual tumor volume of patients with glioblastoma.

Raphael Meier1, Nicole Porz2,3, Urspeter Knecht2, Tina Loosli2, Philippe Schucht3, Jürgen Beck3, Johannes Slotboom2, Roland Wiest2, Mauricio Reyes1.   

Abstract

OBJECTIVE In the treatment of glioblastoma, residual tumor burden is the only prognostic factor that can be actively influenced by therapy. Therefore, an accurate, reproducible, and objective measurement of residual tumor burden is necessary. This study aimed to evaluate the use of a fully automatic segmentation method-brain tumor image analysis (BraTumIA)-for estimating the extent of resection (EOR) and residual tumor volume (RTV) of contrast-enhancing tumor after surgery. METHODS The imaging data of 19 patients who underwent primary resection of histologically confirmed supratentorial glioblastoma were retrospectively reviewed. Contrast-enhancing tumors apparent on structural preoperative and immediate postoperative MR imaging in this patient cohort were segmented by 4 different raters and the automatic segmentation BraTumIA software. The manual and automatic results were quantitatively compared. RESULTS First, the interrater variabilities in the estimates of EOR and RTV were assessed for all human raters. Interrater agreement in terms of the coefficient of concordance (W) was higher for RTV (W = 0.812; p < 0.001) than for EOR (W = 0.775; p < 0.001). Second, the volumetric estimates of BraTumIA for all 19 patients were compared with the estimates of the human raters, which showed that for both EOR (W = 0.713; p < 0.001) and RTV (W = 0.693; p < 0.001) the estimates of BraTumIA were generally located close to or between the estimates of the human raters. No statistically significant differences were detected between the manual and automatic estimates. BraTumIA showed a tendency to overestimate contrast-enhancing tumors, leading to moderate agreement with expert raters with respect to the literature-based, survival-relevant threshold values for EOR. CONCLUSIONS BraTumIA can generate volumetric estimates of EOR and RTV, in a fully automatic fashion, which are comparable to the estimates of human experts. However, automated analysis showed a tendency to overestimate the volume of a contrast-enhancing tumor, whereas manual analysis is prone to subjectivity, thereby causing considerable interrater variability.

Entities:  

Keywords:  BraTumIA; BraTumIA = brain tumor image analysis; CET = contrast-enhancing tumor; CRET = complete resection of the enhancing tumor; EOR = extent of resection; MPR = multiplanar reconstruction; PRET = partial resection of the enhancing tumor; RTV = residual tumor volume; T1w = T1-weighted; T2w = T2-weighted; W = Kendall's coefficient of concordance; automatic tumor volumetry; extent of resection; glioblastoma; oncology; residual tumor volume

Mesh:

Year:  2017        PMID: 28059651     DOI: 10.3171/2016.9.JNS16146

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  14 in total

1.  Semantic imaging features predict disease progression and survival in glioblastoma multiforme patients.

Authors:  Jan C Peeken; Josefine Hesse; Bernhard Haller; Kerstin A Kessel; Fridtjof Nüsslin; Stephanie E Combs
Journal:  Strahlenther Onkol       Date:  2018-02-13       Impact factor: 3.621

2.  Application of deep learning for automatic segmentation of brain tumors on magnetic resonance imaging: a heuristic approach in the clinical scenario.

Authors:  Antonio Di Ieva; Carlo Russo; Sidong Liu; Anne Jian; Michael Y Bai; Yi Qian; John S Magnussen
Journal:  Neuroradiology       Date:  2021-01-26       Impact factor: 2.804

3.  Development and Practical Implementation of a Deep Learning-Based Pipeline for Automated Pre- and Postoperative Glioma Segmentation.

Authors:  E Lotan; B Zhang; S Dogra; W D Wang; D Carbone; G Fatterpekar; E K Oermann; Y W Lui
Journal:  AJNR Am J Neuroradiol       Date:  2021-12-02       Impact factor: 3.825

4.  Impact of postoperative dexamethasone on survival, steroid dependency, and infections in newly diagnosed glioblastoma patients.

Authors:  Akshitkumar M Mistry; Sumeeth V Jonathan; Meredith A Monsour; Bret C Mobley; Stephen W Clark; Paul L Moots
Journal:  Neurooncol Pract       Date:  2021-06-23

Review 5.  Imaging in neuro-oncology.

Authors:  Hari Nandu; Patrick Y Wen; Raymond Y Huang
Journal:  Ther Adv Neurol Disord       Date:  2018-02-28       Impact factor: 6.570

Review 6.  Artificial intelligence in cancer imaging: Clinical challenges and applications.

Authors:  Wenya Linda Bi; Ahmed Hosny; Matthew B Schabath; Maryellen L Giger; Nicolai J Birkbak; Alireza Mehrtash; Tavis Allison; Omar Arnaout; Christopher Abbosh; Ian F Dunn; Raymond H Mak; Rulla M Tamimi; Clare M Tempany; Charles Swanton; Udo Hoffmann; Lawrence H Schwartz; Robert J Gillies; Raymond Y Huang; Hugo J W L Aerts
Journal:  CA Cancer J Clin       Date:  2019-02-05       Impact factor: 508.702

7.  Divide and Conquer: Stratifying Training Data by Tumor Grade Improves Deep Learning-Based Brain Tumor Segmentation.

Authors:  Michael Rebsamen; Urspeter Knecht; Mauricio Reyes; Roland Wiest; Raphael Meier; Richard McKinley
Journal:  Front Neurosci       Date:  2019-11-05       Impact factor: 4.677

8.  Deep learning for glioblastoma segmentation using preoperative magnetic resonance imaging identifies volumetric features associated with survival.

Authors:  Yizhou Wan; Roushanak Rahmat; Stephen J Price
Journal:  Acta Neurochir (Wien)       Date:  2020-07-13       Impact factor: 2.216

Review 9.  Automatic brain lesion segmentation on standard magnetic resonance images: a scoping review.

Authors:  Emilia Gryska; Justin Schneiderman; Isabella Björkman-Burtscher; Rolf A Heckemann
Journal:  BMJ Open       Date:  2021-01-29       Impact factor: 2.692

10.  Fully automated brain resection cavity delineation for radiation target volume definition in glioblastoma patients using deep learning.

Authors:  Ekin Ermiş; Alain Jungo; Robert Poel; Marcela Blatti-Moreno; Raphael Meier; Urspeter Knecht; Daniel M Aebersold; Michael K Fix; Peter Manser; Mauricio Reyes; Evelyn Herrmann
Journal:  Radiat Oncol       Date:  2020-05-06       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.